SML2786
WRG-28
≥98% (HPLC)
别名:
DDR2 inhibitor WRG-28, N-Ethyl-4-[[(3-oxo-3H-phenoxazin-7-yl)oxy]methyl]-benzenesulfonamide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C21H18N2O5S
化学文摘社编号:
分子量:
410.44
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to very dark orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[S](=O)(=O)(NCC)c1ccc(cc1)COc2cc3[o]c4c(nc3cc2)cc[c](c4)=O
InChI key
AARVTLIQNGAELZ-UHFFFAOYSA-N
Biochem/physiol Actions
WRG-28 is a potent, selective and extracellularly acting allosteric inhibitor of discoidin domain receptor 2 (DDR2) that potently inhibits invasion and migration in mice model of breast cancer. WRG-28 inhibits metastatic breast tumor cell colonization in the lungs.
potent, selective and extracellularly acting allosteric inhibitor of DDR2 that potently inhibits invasion and migration tumor cells
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Saumya S Gurbani et al.
Tomography (Ann Arbor, Mich.), 5(1), 53-60 (2019-03-12)
Histone deacetylases regulate a wide variety of cellular functions and have been implicated in redifferentiation of various tumors. Histone deacetylase inhibitors (HDACi) are potential pharmacologic agents to improve outcomes for patients with gliomas. We assessed the therapeutic efficacy of belinostat
Pengwei Lu et al.
Artificial cells, nanomedicine, and biotechnology, 47(1), 3955-3960 (2019-10-02)
Belinostat is a histone deacetylase inhibitor drug capable of regulating cell growth in diverse cancers. Nonetheless, little information clarified the role of Belinostat in breast cancer. Hence, the functions of Belinostat in breast cancer cells survival was disclosed in this
Xiaoyan Qiu et al.
Cellular reprogramming, 22(1), 14-21 (2020-02-06)
To improve the isolation efficiency of parthenogenetic embryonic stem cells (pESCs) in mice, it is necessary to optimize the method to increase in vitro developmental competence of mice parthenogenetic blastocysts. Therefore, this study aims to investigate an optimal method for
Frank C Passero et al.
British journal of haematology, 188(2), 295-308 (2019-08-28)
Ixazomib activity and transcriptomic analyses previously established in T cell (TCL) and Hodgkin (HL) lymphoma models predicted synergistic activity for histone deacetylase (HDAC) inhibitory combination. In this present study, we determined the mechanistic basis for ixazomib combination with the HDAC
Francesco Marampon et al.
Cancer letters, 461, 90-101 (2019-07-22)
This study describes the in vitro and in vivo activity of PXD-101 (Belinostat), a novel hydroxamic acid-type pan-HDACs inhibitor characterized by a larger safety and efficacy, on myogenic-derived PAX3/FOXO1 fusion protein positive (RH30) or negative (RD) expressing rhabdomyosarcoma (RMS) cell
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2786-25MG | 04065265632423 |
| SML2786-5MG | 04065265632430 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持